


**Hepatology COVID-19 Registry**  
**Week 3 Report**  
**6 new cases added**


	<b>Chronic liver disease (N=9)</b>	<b>Post-liver transplantation (N=8)</b>
<b>Gender (%)</b>	Female = 4 (44.5%) Male = 5 (55.5%)	Female = 4 (50%) Male = 4 (50%)
<b>Median Age (yr) at time of COVID diagnosis (range)</b>	5 (0.25-15)	12 (1-21)
<b>Etiology of liver disease</b>	Biliary atresia = 4 Autoimmune hepatitis = 1 NAFLD = 2 Idiopathic cholestasis = 1 Metabolic disorder = 1	Biliary atresia = 4 Acute liver failure = 2 Metabolic disorders = 1 Tumor = 1
<b>Highest level of care</b>		
Outpatient	3	6
Hospital floor	5	2
ICU	1	0
<b>Immunosuppression at time of COVID diagnosis</b> (*some patients were on multiple agents)	Azathioprine = 1 No Immunosuppression = 8	Tacrolimus = 6 Sirolimus = 1 Steroids = 3 Mycophenolate Mofetil = 4 Cyclosporine = 1
<b>Specific Treatment for COVID</b> (*some patients were on multiple agents)	Hydroxychloroquine + Azithromycin = 2 IVIG = 1 Tocilizumab and Sarilumab = 1	Azithromycin = 1
<b>Highest respiratory support</b>		
None	6	7
Nasal cannula/CPAP/BiPAP	1	0
Mechanical ventilation	1	0
Still active in clinical course	1	1
<b>Final clinical outcome</b>		
Death	0	0
Recovery	7	6
Still active in clinical course	2	2
<b>Liver related Complications</b>	Ascites = 3 Variceal bleeding = 1 None = 5	None = 7

### Presenting symptoms at time of diagnosis




\* Other symptoms reported: malaise, reduced oral intake

### Baseline ALT levels (CLD + Post liver transplant group)



\* Red dot denotes median, blue dots individual levels (median ALT 37, range 19-200)


### Change done to Immunosuppressive agent (Post liver transplant group)



\*Stopped, decreased the dose, others and no changes

Most common agent **stopped**: Mycophenolate Mofetil

### Peak ALT Levels (CLD + Post liver transplant Group)



\*Red dot denotes median, blue dots individual values (median ALT 95, range 20-424)